Cargando…

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas

Epithelial ovarian cancer is a diverse molecular and clinical disease, yet standard treatment is the same for all subtypes. TP53 mutations represent a node of divergence in epithelial ovarian cancer histologic subtypes and may represent a therapeutic opportunity in subtypes expressing wild type, inc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crane, Erin K., Kwan, Suet-Yan, Izaguirre, Daisy I., Tsang, Yvonne T. M., Mullany, Lisa K., Zu, Zhifei, Richards, JoAnne S., Gershenson, David M., Wong, Kwong-Kwok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527847/ https://www.ncbi.nlm.nih.gov/pubmed/26248031 http://dx.doi.org/10.1371/journal.pone.0135101

Ejemplares similares

Specific TP53 Mutants Overrepresented in Ovarian Cancer Impact CNV, TP53 Activity, Responses to Nutlin-3a, and Cell Survival()
por: Mullany, Lisa K., et al.
Publicado: (2015)

The Role of GDF15 in Regulating the Canonical Pathways of the Tumor Microenvironment in Wild-Type p53 Ovarian Tumor and Its Response to Chemotherapy
por: Izaguirre, Daisy I., et al.
Publicado: (2020)

PAX2 Expression in Ovarian Cancer
por: Song, Huijuan, et al.
Publicado: (2013)

Loss of ARID1A expression leads to sensitivity to ROS-inducing agent elesclomol in gynecologic cancer cells
por: Kwan, Suet-Yan, et al.
Publicado: (2016)

Nutlin‐3a selects for cells harbouring TP 53 mutations
por: Kucab, Jill E., et al.
Publicado: (2016)

Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application
por: Pozzo, Federico, et al.
Publicado: (2013)

Protection of p53 wild type cells from taxol by nutlin-3 in the combined lung cancer treatment
por: Tokalov, Sergey V, et al.
Publicado: (2010)

Awakening p53 in senescent cells using nutlin-3
por: Schug, Thaddeus T.
Publicado: (2009)

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
por: Aziz, Moammir H., et al.
Publicado: (2011)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL
por: Meijer, A, et al.
Publicado: (2013)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

PAX2 Expression in Low Malignant Potential Ovarian Tumors and Low-Grade Ovarian Serous Carcinomas
por: Tung, Celestine S., et al.
Publicado: (2009)

TP53BP2: Roles in suppressing tumorigenesis and therapeutic opportunities
por: Huo, Yunfei, et al.
Publicado: (2022)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
por: Gamble, Laura D., et al.
Publicado: (2011)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
por: Sriraman, Anusha, et al.
Publicado: (2016)

Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
por: Lee, Dong Min, et al.
Publicado: (2017)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

Activation of p53 by Nutlin-3a Induces Apoptosis and Cellular Senescence in Human Glioblastoma Multiforme
por: Villalonga-Planells, Ruth, et al.
Publicado: (2011)

Nutlin-3 downregulates p53 phosphorylation on serine(392) and induces apoptosis in hepatocellular carcinoma cells
por: Shi, Xinli, et al.
Publicado: (2014)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia
por: Haaland, Ingvild, et al.
Publicado: (2014)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients
por: Kwong, Ava, et al.
Publicado: (2020)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
por: Valentine, Jane M, et al.
Publicado: (2011)

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma
por: Zheng, Tongsen, et al.
Publicado: (2014)

Nutlin-3a Nanodisks Induce p53 Stabilization and Apoptosis in a Subset of Cultured Glioblastoma Cells
por: Krishnamoorthy, A, et al.
Publicado: (2017)

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
por: Azer, Samy A.
Publicado: (2018)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8u0us450cfug9pa8rcl6132nip